The FDA's Drugs@FDA database lists a supplement dated 29 September 2026 to an abbreviated new drug application for rifampin, held by a generic manufacturer. The entry gives the application number and company only. It does not state what the supplement changed, so nothing here describes a new indication, a safety communication or a label change.
For clinicians the entry is a reminder rather than news: rifampin is a long-established drug, and a supplement to a generic application is administrative unless the label text itself changes. Check the product label if you rely on a specific formulation.
In India, prescribers use rifampicin through the national TB programme and local formularies; CDSCO has said nothing in this record, and an FDA generic supplement does not alter Indian practice or availability.
- The entry names the application and manufacturer but not the change made.
- It is not a new indication or a safety warning.
- Rely on your national TB programme and local formulary for rifampicin dosing and supply.
- Check the label of the specific product you dispense if the change affects formulation or storage.
Why it matters
It separates a routine administrative filing from a regulatory action that changes prescribing.
Don't overread it
A supplement to a generic application is not a new indication, and the record does not say what was changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free